Improving the quality of care for depressed patients with comorbid psychiatric disorders: a review.
Comorbidity of depression complicates diagnosis and makes treatment more difficult. The broad efficacy of selective-seratonin reuptake inhibitors makes these compounds of particular benefit as monotherapy for depression comorbid with anxiety disorders, especially panic disorder and obsessive-compulsive disorder.
Dunner
D L
DL
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98105, USA.
D001008:Anxiety Disorders / Q000188:drug therapy* / Q000453:epidemiology; D015897:Comorbidity; D003362:Cost-Benefit Analysis; D003866:Depressive Disorder / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology*; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy; D016584:Panic Disorder / Q000188:drug therapy; D011320:Primary Health Care / Q000191:economics / Q000592:standards; D011787:Quality of Health Care; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology